Yuliya Berd

514 total citations
7 papers, 379 citations indexed

About

Yuliya Berd is a scholar working on Oncology, Rheumatology and Molecular Biology. According to data from OpenAlex, Yuliya Berd has authored 7 papers receiving a total of 379 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Rheumatology and 2 papers in Molecular Biology. Recurrent topics in Yuliya Berd's work include Bone health and treatments (4 papers), Spondyloarthritis Studies and Treatments (2 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Yuliya Berd is often cited by papers focused on Bone health and treatments (4 papers), Spondyloarthritis Studies and Treatments (2 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Yuliya Berd collaborates with scholars based in United States, Denmark and New Zealand. Yuliya Berd's co-authors include Weili He, Antonio Lombardi, Sean Curtis, Anjela Tzontcheva, Christopher Wynne, Désirée van der Heijde, B. B. Scott, Judith A. Boice, Hsu‐Huei Weng and Maxime Dougados and has published in prestigious journals such as Journal of Clinical Oncology, Lara D. Veeken and Cancer Treatment Reviews.

In The Last Decade

Yuliya Berd

7 papers receiving 368 citations

Peers

Countries citing papers authored by Yuliya Berd

Since Specialization

Citations

This map shows the geographic impact of Yuliya Berd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuliya Berd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuliya Berd more than expected).

Fields of papers citing papers by Yuliya Berd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuliya Berd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuliya Berd. The network helps show where Yuliya Berd may publish in the future.

Co-authorship network of co-authors of Yuliya Berd

This figure shows the co-authorship network connecting the top 25 collaborators of Yuliya Berd. A scholar is included among the top collaborators of Yuliya Berd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuliya Berd. Yuliya Berd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK) 2023 ·Lara D. Veeken ·(unknown), (unknown), (unknown), Marina Stanislav, Anjela Tzontcheva, Ruji Yao, Yuliya Berd, Sean Curtis, George Philip	8
2	A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis 2015 ·Arthritis & Rheumatology ·Joachim Sieper, Désirée van der Heijde, Maxime Dougados, Walter P. Maksymowych, B. B. Scott, Judith A. Boice, Yuliya Berd, G. Bergman, Sean Curtis, Anjela Tzontcheva, Susan Huyck, Hsu‐Huei Weng	160
3	The Cathepsin K Inhibitor Odanacatib Suppresses Bone Resorption in Women With Breast Cancer and Established Bone Metastases: Results of a 4-Week, Double-Blind, Randomized, Controlled Trial 2010 ·Clinical Breast Cancer ·Anders Bonde Jensen, Christopher Wynne, Guillermo Ramírez, Weili He, (unknown), Yuliya Berd, Hongwei Wang, (unknown), Antonio Lombardi	105
4	Evaluation of the safety, pharmacokinetics and treatment effects of an α_νβ₃ integrin inhibitor on bone turnover and disease activity in men with hormone‐refractory prostate cancer and bone metastases 2010 ·Asia-Pacific Journal of Clinical Oncology ·Mark Rosenthal, Peter J. Davidson, Frédéric Rolland, Mario Campone, (unknown), Tae Hyung Han, Anish Mehta, Yuliya Berd, Weili He, Antonio Lombardi	40
5	MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: A multicenter, randomized, placebo-controlled phase IIb study 2010 ·Archives of Gerontology and Geriatrics ·Abraham Adunsky, Julie Chandler, Norman Heyden, (unknown), Boyd B. Scott, Yuliya Berd, Nancy Liu, Dimitris A. Papanicolaou	46
6	Effect of cathepsin k inhibition on suppression of bone resorption in women with breast cancer and established bone metastases in a 4-week, double-blind, randomized controlled trial 2008 ·Journal of Clinical Oncology ·(unknown), N. Olmeo, Christopher Wynne, (unknown), Antje Lebrecht, (unknown), (unknown), (unknown), Yuliya Berd, Assunta Lombardi	19
7	OC2. Efficacy, pharmacokinetics, and safety of a cathepsin K (Cat K) inhibitor in the suppression of bone resorption in women with breast cancer and established bone 2 2008 ·Cancer Treatment Reviews ·Christopher Wynne, Anders Bonde Jensen, Steinar Lundgren, (unknown), (unknown), (unknown), (unknown), Shabana Ather, Weili He, (unknown), Yuliya Berd, Antonio Lombardi	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact